The Cinnamon in Your Kitchen Is Almost Certainly the Wrong One for Daily Use
There are two species sold as “cinnamon.” One carries a coumarin load up to 1,200 times higher than the other — and it’s the one on almost every Malaysian shelf.
Cinnamon’s reputation as a blood-sugar spice isn’t folklore — it has a documented receptor mechanism, a landmark clinical trial, and even a published trial comparing it to ibuprofen for period pain. But almost none of that evidence applies safely to daily high-dose use unless you know which species you’re holding. This article covers the mechanism, the trial data, the species distinction that actually matters, and where the honest limits are.
Think of your cells as having a lock on their surface that insulin uses as a key to let blood sugar in.
When insulin fits into that lock — the insulin receptorA protein on the surface of cells that insulin binds to, triggering the cell to absorb glucose from the blood. — it changes shape and tells the cell to start pulling glucose out of the bloodstream. In diabetes, this system doesn’t respond as well as it should. A compound in cinnamon called MHCP has been shown to activate this same lock-and-key system directly — mimicking part of what insulin itself does. That’s the mechanism behind cinnamon’s blood-sugar reputation, and it’s worth understanding properly before deciding what it does and doesn’t mean for you.
Five Facts That Reframe an Ordinary Spice
- Cassia cinnamon carries coumarin at 2,100–4,400 ppm — Ceylon carries essentially none (0–10 ppm). That’s a difference of roughly 10x to over 400x, depending on the batch.
- Almost all cinnamon sold in Malaysia is Cassia, not Ceylon — the species distinction is rarely made on the label.
- MHCP, a compound unique to cinnamon, activates insulin receptor tyrosine kinase — the same signalling pathway insulin itself uses.
- A published clinical trial compared cinnamon directly to ibuprofen for period pain and found comparable results.
- For a 60kg adult, roughly 2 grams of Cassia cinnamon a day approaches the European Food Safety Authority’s Tolerable Daily Intake for coumarin.
Five Things That Reframe Cinnamon
Cinnamon isn’t one plant — it’s two species sold under one name, and only one of them is appropriate for daily therapeutic use.
Cinnamomum verum (Ceylon, “true cinnamon”) and Cinnamomum cassia (Cassia) are botanically distinct species that both end up labelled simply “cinnamon” on supermarket shelves. They share therapeutic compounds, but differ sharply in one that matters: coumarin.
The blood-sugar effect has a documented receptor mechanism, not just a folk reputation.
MHCP (methylhydroxychalcone polymer) activates insulin receptor tyrosine kinase — the same pathway insulin uses to signal cells to absorb glucose (Jarvill-Taylor et al., 2001). A landmark 2003 trial (Khan et al., Diabetes Care) documented measurable glucose and lipid improvements in people with type 2 diabetes over 40 days.
Cinnamaldehyde — the compound behind cinnamon’s aroma — works through the same mechanistic class as ibuprofen.
Cinnamaldehyde inhibits prostaglandin synthesis, the same pathway NSAIDs target. A 2015 trial (Jaafarpour et al.) compared cinnamon directly to ibuprofen for primary dysmenorrhoea and found comparable outcomes for pain, nausea, and vomiting.
The morning-sneezing petua involving cloves and cinnamon addresses inflammation through two separate pathways at once.
Cinnamaldehyde inhibits NF-κB activation, reducing pro-inflammatory cytokines that sustain nasal inflammation — a different, complementary pathway to eugenol’s antihistamine action from cloves. One upstream, one downstream, working simultaneously.
Ceylon has the same therapeutic compounds as Cassia without the coumarin concern — but knowing how to tell them apart is what makes daily use safe.
Ceylon quills are thin, papery, multi-layered, and crumble easily — lighter tan in colour, delicate in flavour. Cassia is a hard, thick, single-scrolled stick, reddish-brown, stronger in flavour. For daily therapeutic doses, Ceylon is the appropriate choice. For occasional culinary use, either is fine.
Kayu Manis — But Which One?
“Sweet wood.” Both Ceylon and Cassia are sold as kayu manis in Malaysian markets — the distinction is rarely made on the label. The Cassia variety dominates market availability.
Used in Traditional Chinese Medicine for centuries, typically referring to Cassia bark — classified as a warming herb in TCM theory.
“True cinnamon” — thin, multi-layered quills, negligible coumarin, the appropriate species for daily therapeutic protocols.
The dominant commercial species worldwide — thick single-scroll bark, stronger flavour, meaningfully higher coumarin content.
Kayu Manis in Every Rempah — Without the Species Distinction
Kayu manis is a fixture of Malaysian cooking across ethnic traditions — in Malay rendang and kurma, in Indian biryani and masala chai, in Peranakan kuih. It appears as a whole stick simmered into gravies or ground into spice pastes, almost always without any indication of which species is in the packet.
For culinary use — a stick or two in a pot of rendang, occasional cups of cinnamon tea — this distinction rarely matters. The coumarin concern is a cumulative daily-dose issue, not a one-off exposure issue. It becomes relevant the moment kayu manis moves from seasoning to a daily therapeutic protocol, such as the cinnamon water tradition for blood sugar management.
The wrong default is treating “kayu manis” as a single ingredient — rather than two botanically distinct species with meaningfully different safety profiles at therapeutic doses. Identifying which one is in your kitchen is a five-second visual check, not a laboratory test.
What’s Actually Documented
Methylhydroxychalcone polymer activates insulin receptor tyrosine kinase — mimicking part of insulin’s own signalling mechanism (Jarvill-Taylor et al., 2001).
1–6g Cassia cinnamon daily documented measurable improvements in fasting glucose and lipids in people with type 2 diabetes, in a landmark trial published in Diabetes Care.
Cinnamaldehyde inhibits prostaglandin synthesis — the same mechanistic class ibuprofen uses — underlying the documented period-pain trial result.
The range of coumarin concentration difference between Cassia and Ceylon, depending on batch and source — the basis for the EFSA daily intake guidance.
Six Claims. Six Verdicts.
“Ceylon and Cassia are basically the same thing — the naming is just marketing.”
Ceylon (C. verum) and Cassia (C. cassia/aromaticum) are botanically distinct species. Ceylon has negligible coumarin, a delicate flavour, and thin multi-layered quills. Cassia has 2,100–4,400ppm coumarin, a stronger flavour, and a thick single-scroll bark. Both share the therapeutic compounds — MHCP for insulin sensitisation, cinnamaldehyde for anti-inflammatory activity — but the hepatotoxic coumarin concern is Cassia-specific. The species distinction is pharmacologically and safety-critically meaningful for anyone using cinnamon therapeutically at daily doses.
“Cinnamon water cures diabetes.”
Multiple RCTs confirm modest reductions in fasting glucose and HbA1c. The MHCP mechanism is characterised — this is a real pharmacological effect. “Cures” overstates this dramatically: the effect size isn’t pharmaceutical-scale, evidence is heterogeneous across trials, and cinnamon doesn’t address the progressive β-cell dysfunction underlying Type 2 diabetes. A meaningful dietary complement — not a cure. Treating it as a cure at the expense of medical management causes harm.
“Cinnamon is completely safe to take in large amounts daily — it’s just a food.”
Culinary doses in cooking are safe. High-dose daily supplementation with Cassia cinnamon raises a documented coumarin hepatotoxicity concern. The EFSA Tolerable Daily Intake (0.1mg/kg/day) is approached or exceeded by roughly 2g of Cassia daily in a typical 60kg adult. Case reports of liver damage from high-dose Cassia supplements exist (German BfR, 2006). “It’s just a food” logic doesn’t account for the concentration difference between a cooking spice and a daily therapeutic supplement.
“Cinnamon for period pain is just traditional comfort — it doesn’t really work.”
A 2015 randomised controlled trial (Jaafarpour et al.) directly compared cinnamon to ibuprofen for primary dysmenorrhoea and found comparable outcomes for pain intensity, nausea, and vomiting. The mechanism — cinnamaldehyde inhibition of prostaglandin synthesis — is the same mechanistic class as ibuprofen’s anti-inflammatory effect for period pain. The trial dose (420mg three times daily) is higher than a cup of tea delivers, so tea preparations provide milder benefit. But the pharmacological mechanism is documented and the clinical trial is published. “Just traditional comfort” isn’t accurate.
“Cinnamon and honey together is a superfood combination that boosts everything.”
Cinnamon has documented insulin-sensitising and anti-inflammatory effects. Honey has documented antimicrobial, wound-healing, and antioxidant effects. Both have independent pharmacological activity. However, “boosts everything” combined superfood claims are marketing rhetoric, not pharmacology. The two together deliver their respective compound matrices — cinnamon’s cinnamaldehyde and MHCP, honey’s phenolics and glucose oxidase — but they don’t produce a synergistic super-effect beyond their individual mechanisms. Honey also adds caloric load, counterproductive for the weight-loss angle of the combination.
“Ceylon cinnamon has no medicinal effect — only Cassia does because it’s stronger.”
Ceylon contains the same MHCP (insulin receptor activator), cinnamaldehyde (anti-inflammatory, antimicrobial, prostaglandin inhibitor), procyanidins, and other therapeutic compounds as Cassia. Cassia has a modestly higher cinnamaldehyde percentage in its essential oil (up to 95% vs 55–90% in Ceylon) — that’s not the same as Ceylon having no effect. Most importantly, Ceylon has essentially zero coumarin, making it the appropriate choice for therapeutic daily doses. “Stronger equals better” logic fails when the stronger component — higher coumarin in Cassia — is the hepatotoxic one.
How to Use Cinnamon
Species selection matters for therapeutic applications. For all daily high-dose therapeutic uses: Ceylon, not Cassia. Identify your cinnamon before starting any daily supplementation protocol.
Method: Soak one Ceylon cinnamon stick in 2 cups of cold water overnight. Drink the water in the morning on an empty stomach. Or steep ½ tsp Ceylon powder in hot water for 10 minutes, strain, and drink.
Species: Ceylon specifically — thin, crumbly, tan quills.
Method: Simmer one Ceylon cinnamon stick in 2 cups of water for 10 minutes. Drink 2–3 cups daily during the first days of the cycle. Note this delivers a milder dose than the 420mg trial dose.
Method: Simmer 1 Ceylon cinnamon stick with 3–4 whole cloves in 2 cups of water for 10 minutes. Strain and drink warm. Addresses inflammation through two independent pathways simultaneously.
Method: Whole sticks in rendang, kurma, and biryani; ground powder in baking and masala chai. Either species is appropriate for occasional culinary quantities — the coumarin concern is a cumulative daily-dose issue, not a one-off exposure.
Heterogeneous clinical trial evidence for blood sugar: Not all cinnamon trials show significant glucose improvement — results vary by species, dose, form (whole, extract, powder), and patient population. The current meta-analysis consensus (Allen et al. 2013; Davis & Yokoyama 2011) shows a modest but significant average effect. Individual responses vary. This is not a guaranteed intervention.
Coumarin in Cassia — real but context-dependent: The hepatotoxicity risk is real but dose-dependent and susceptibility-dependent. Most people consuming culinary Cassia quantities will never experience liver problems. The specific risk is for high-dose daily supplementation over months, particularly in individuals with pre-existing liver conditions or those taking hepatotoxic medications concurrently.
Period pain trial is a single study: The Jaafarpour et al. (2015) trial is encouraging but needs replication at larger scale. The mechanistic basis is sound. The clinical evidence base is promising but not yet at clinical guideline-level recommendation.
Drug interactions: Cinnamon has mild antiplatelet activity (from cinnamaldehyde) and blood-glucose-lowering effects. Concurrent use with warfarin or anticoagulants warrants monitoring. Concurrent use with diabetes medication requires medical supervision — additive blood-glucose lowering from both sources can cause hypoglycaemia.
This article is educational, not medical advice. Do not stop or adjust diabetes medication, blood thinners, or any prescribed treatment based on this content without consulting your doctor. Pregnant or breastfeeding women should use therapeutic-dose cinnamon only under medical guidance. If you are unsure which cinnamon species you have, treat it as Cassia and limit daily intake accordingly.
References & Sources ↓
- Khan A, et al. (2003). Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 26(12):3215–3218. Cassia 1–6g/day, 40 days. Landmark blood sugar trial.
- Jaafarpour M, et al. (2015). Comparative effect of cinnamon and ibuprofen for treatment of primary dysmenorrhea. Journal of Clinical and Diagnostic Research 9(4):QC04–QC07.
- EFSA (2004). Coumarin Tolerable Daily Intake: 0.1mg/kg body weight/day. Cassia coumarin content: 2,100–4,400ppm. Ceylon coumarin: 0–10ppm.
- Jarvill-Taylor KJ, et al. (2001). A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. Journal of the American College of Nutrition 20(4):327–336.
- Cinnamaldehyde: documented NF-κB inhibitory anti-inflammatory activity, prostaglandin synthesis inhibition, broad-spectrum antimicrobial activity, TRPV1 activation.
- Meta-analyses of cinnamon for Type 2 diabetes: Allen RW, et al. (2013), Annals of Family Medicine; Davis PA, Yokoyama W (2011), Journal of Medicinal Food. Modest, significant reductions in fasting glucose and HbA1c confirmed.
- German BfR warning (2006). Case reports of liver damage associated with high-dose Cassia cinnamon supplements.